TY  - JOUR
  - O'Connell, J.,Bennett, M. W.,O'Sullivan, G. C.,O'Callaghan, J.,Collins, J. K.,Shanahan, F.
  - 1999
  - July
  - Expression of fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege
  - Validated
  - ()
  - 6
  - 44
  - 457
  - 463457
  - Breast canters have been shown to elicit tumor-specific immune responses, As in other types of cancer, the antitumor immune response fails to contain breast tumor growth, and a reduction in both the quantity and cytotoxic effectiveness of tumor-infiltrating lymphocytes (TILs) is associated with a poorer prognosis. Fas ligand (FasL) induces apoptotic death of activated lymphocytes that express its cell surface receptor, FasR (CD95/APO-1), Fast-mediated apoptosis of activated lymphocytes contributes to normal immune downregulation through its roles in tolerance acquisition, immune response termination, and maintenance of immune privilege in the eye, testis, and fetus, In this report, we demonstrate that breast carcinomas express Fast. Using in situ hybridization and immunohistochemistry, we show that breast tumors constitutively express Fast at both the mRNA and protein levels, respectively. Fast expression is prevalent in breast cancer: 100% of breast tumors (17 of 17) were found to express Fast, and expression occurred over more than 50% of the tumor area in all cases. By immunohistochemistry, FasR was found to be coexpressed with Fast throughout large areas of all the breast tumors. This suggests that the tumor cells had acquired intracellular defects in Fast-mediated apoptotic signaling. Fast and FasR expression were independent of tumor type or infiltrative capacity. Fast expressed by tumor cells has previously been shown to kill Fas-sensitive lymphoid cells in vitro and has been associated with apoptosis of TILs in vivo. We conclude that mammary carcinomas express Fast in vivo as a potential inhibitor of the antitumor immune response.Breast canters have been shown to elicit tumor-specific immune responses, As in other types of cancer, the antitumor immune response fails to contain breast tumor growth, and a reduction in both the quantity and cytotoxic effectiveness of tumor-infiltrating lymphocytes (TILs) is associated with a poorer prognosis. Fas ligand (FasL) induces apoptotic death of activated lymphocytes that express its cell surface receptor, FasR (CD95/APO-1), Fast-mediated apoptosis of activated lymphocytes contributes to normal immune downregulation through its roles in tolerance acquisition, immune response termination, and maintenance of immune privilege in the eye, testis, and fetus, In this report, we demonstrate that breast carcinomas express Fast. Using in situ hybridization and immunohistochemistry, we show that breast tumors constitutively express Fast at both the mRNA and protein levels, respectively. Fast expression is prevalent in breast cancer: 100% of breast tumors (17 of 17) were found to express Fast, and expression occurred over more than 50% of the tumor area in all cases. By immunohistochemistry, FasR was found to be coexpressed with Fast throughout large areas of all the breast tumors. This suggests that the tumor cells had acquired intracellular defects in Fast-mediated apoptotic signaling. Fast and FasR expression were independent of tumor type or infiltrative capacity. Fast expressed by tumor cells has previously been shown to kill Fas-sensitive lymphoid cells in vitro and has been associated with apoptosis of TILs in vivo. We conclude that mammary carcinomas express Fast in vivo as a potential inhibitor of the antitumor immune response.
  - 1071-412X1071-412X
  - ://WOS:000081382100003://WOS:000081382100003
DA  - 1999/07
ER  - 

@article{V235379756,
   = {O'Connell,  J. and Bennett,  M. W. and O'Sullivan,  G. C. and O'Callaghan,  J. and Collins,  J. K. and Shanahan,  F. },
   = {1999},
   = {July},
   = {Expression of fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege},
   = {Validated},
   = {()},
   = {6},
   = {44},
  pages = {457--463457},
   = {{Breast canters have been shown to elicit tumor-specific immune responses, As in other types of cancer, the antitumor immune response fails to contain breast tumor growth, and a reduction in both the quantity and cytotoxic effectiveness of tumor-infiltrating lymphocytes (TILs) is associated with a poorer prognosis. Fas ligand (FasL) induces apoptotic death of activated lymphocytes that express its cell surface receptor, FasR (CD95/APO-1), Fast-mediated apoptosis of activated lymphocytes contributes to normal immune downregulation through its roles in tolerance acquisition, immune response termination, and maintenance of immune privilege in the eye, testis, and fetus, In this report, we demonstrate that breast carcinomas express Fast. Using in situ hybridization and immunohistochemistry, we show that breast tumors constitutively express Fast at both the mRNA and protein levels, respectively. Fast expression is prevalent in breast cancer: 100% of breast tumors (17 of 17) were found to express Fast, and expression occurred over more than 50% of the tumor area in all cases. By immunohistochemistry, FasR was found to be coexpressed with Fast throughout large areas of all the breast tumors. This suggests that the tumor cells had acquired intracellular defects in Fast-mediated apoptotic signaling. Fast and FasR expression were independent of tumor type or infiltrative capacity. Fast expressed by tumor cells has previously been shown to kill Fas-sensitive lymphoid cells in vitro and has been associated with apoptosis of TILs in vivo. We conclude that mammary carcinomas express Fast in vivo as a potential inhibitor of the antitumor immune response.Breast canters have been shown to elicit tumor-specific immune responses, As in other types of cancer, the antitumor immune response fails to contain breast tumor growth, and a reduction in both the quantity and cytotoxic effectiveness of tumor-infiltrating lymphocytes (TILs) is associated with a poorer prognosis. Fas ligand (FasL) induces apoptotic death of activated lymphocytes that express its cell surface receptor, FasR (CD95/APO-1), Fast-mediated apoptosis of activated lymphocytes contributes to normal immune downregulation through its roles in tolerance acquisition, immune response termination, and maintenance of immune privilege in the eye, testis, and fetus, In this report, we demonstrate that breast carcinomas express Fast. Using in situ hybridization and immunohistochemistry, we show that breast tumors constitutively express Fast at both the mRNA and protein levels, respectively. Fast expression is prevalent in breast cancer: 100% of breast tumors (17 of 17) were found to express Fast, and expression occurred over more than 50% of the tumor area in all cases. By immunohistochemistry, FasR was found to be coexpressed with Fast throughout large areas of all the breast tumors. This suggests that the tumor cells had acquired intracellular defects in Fast-mediated apoptotic signaling. Fast and FasR expression were independent of tumor type or infiltrative capacity. Fast expressed by tumor cells has previously been shown to kill Fas-sensitive lymphoid cells in vitro and has been associated with apoptosis of TILs in vivo. We conclude that mammary carcinomas express Fast in vivo as a potential inhibitor of the antitumor immune response.}},
  issn = {1071-412X1071-412X},
   = {://WOS:000081382100003://WOS:000081382100003},
  source = {IRIS}
}